Sergio Iadevaia Email & Phone Number

Radnor, Pennsylvania, US

Cambridge, MA, US

Provided strategic pharmacometrics input and subject-matter expertise for the design of clinical studies across the Relay portfolioPlanned and executed exposure/efficacy and exposure/safety analyses to optimize RLY-4008 dose regimens and support dose selection for filing of breakthrough therapy designation to the FDAInitiated the development of a.

Boston, MA, US

Developed analysis plans, provided strategic modeling input and delivered high-quality hands-on analyses to guide the design of ph2 and ph3 studies in acute pain (bunionectomy and abdominoplasty)Effectively communicated modeling results to cross-functional teams and all levels of management, represented Modeling and Simulation function in highly-matrixed.

Tokyo, JP

Managed the development of QSP platforms for celiac disease and for Crohn's diseaseConstructed a QSP modeling platform that links key neuronal circuitry and neurotransmitters involved in emesis pathophysiology with the effects of neural and humoral inputs in relevant compartments and the mechanisms of action of selected therapies. The platform was used to.

Tokyo, JP

Assembled a QSP model that connects systemic dosing of DAAO inhibitors to D-serine increase in the cerebellum to activation of NMDAR signaling to modulation of clinical outcomes, such as SANS and PANSS negative. The model guided dose selection for a phase 2 study in subjects with stable schizophreniaDeveloped a population PK model to establish TAK-653.

Cambridge, Massachusetts, US

Led computational efforts to forecast clinical analytics, including timelines, budget and drug supply necessary to complete clinical trialsDesigned biomarker-based clinical trials in collaboration with clinical teams and statisticians. Conducted extensive scenario analyses to optimize trial design. Participated in identifying biomarker cut-points to.

Cambridge, Massachusetts, US

Performed statistical analysis to identify biomarkers in translational and clinical settingsConducted population PK studies to support the decision to change MM-141 regimen from weight-based to fixed dosing in the ongoing CARRIE Phase 2 trialLed modeling efforts that supported the decision of administering MM-141 in combination with everolimus to patients.

Cambridge, Massachusetts, US

Formulated and developed mechanistic models to rationalize the mechanism of actions of therapeutics and identify optimal therapeutic combinations targeting large-scale signaling networks Used noncompartmental and PK/PD analysis to optimize drug dosing and scheduling in translational in vivo experiments. Participated in writing PK documentation to support.

Cambridge, Massachusetts, US

Formulated and developed mechanistic models to rationalize the mechanism of actions of therapeutics and identify optimal therapeutic combinations targeting large-scale signaling networks Used noncompartmental and PK/PD analysis to optimize drug dosing and scheduling in translational in vivo experiments.Applied statistical modeling to identity and validate.

Houston, TX, US

Engineered mechanistic models to identify optimal therapeutic combinations targeting large-scale signaling networksValidated predicted drug combinations in human cancer cell lines using immunoblotting, reverse phase protein arrays, and cell viability assaysFormulated stochastic models to predict the dynamics of signaling networks in individual cancer.

Houston, TX, US

Independently taught the course on Dynamics and Process Control (CHBE 470) to senior engineersManaged and organized the process control laboratory. Designed review sessions; graded midterm and final exams

Doctor Of Philosophy (Ph.D.), Chemical And Biomolecular Engineering

Laurea, Chemical Engineering